List of Excipients in Branded Drug NATAZIA

Natazia Excipient Strategy and Commercial Opportunities

Last updated: October 8, 2026

Natazia is a four-phase combined oral contraceptive containing estradiol valerate and dienogest. Its commercial value is tied to a complex 28-day regimen, multiple hormone strengths, color-coded tablets, and the need for consistent dissolution across low-dose hormone tablets. The principal excipient opportunities are in film coating, color differentiation, low-dose content uniformity, tablet robustness, packaging, and generic-equivalent manufacturing.

Natazia’s formulation does not depend on a novel delivery platform. Its defensibility is more likely to arise from product-specific manufacturing controls, tablet identification, process know-how, and regulatory execution than from a broad excipient composition patent.

What is Natazia and how does its dosage form affect excipient strategy?

Natazia is an oral contraceptive marketed by Bayer HealthCare Pharmaceuticals. The product uses four hormone-containing tablet phases followed by two inactive tablets in a 28-tablet blister pack.[1]

Tablet phase	Estradiol valerate	Dienogest	Commercial formulation issue
Phase 1	3 mg	0 mg	Low-dose hormone uniformity and tablet identification
Phase 2	2 mg	2 mg	Dual-active compatibility and content uniformity
Phase 3	2 mg	3 mg	Highest dienogest load among active phases
Phase 4	0 mg	1 mg	Single-active low-dose control
Inactive phase	0 mg	0 mg	Visual differentiation and regimen adherence

Natazia contains five tablet types in one blister presentation. This increases manufacturing complexity compared with monophasic contraceptives, which generally use one active tablet strength plus placebo tablets.

The formulation strategy must solve four technical problems:

1. Maintain uniform distribution of very low quantities of steroid hormones.
2. Prevent cross-contamination between tablet strengths.
3. Provide sufficient tablet hardness without slowing dissolution.
4. Make each phase visually distinct and easy for patients to identify.

What excipients are used in Natazia?

The U.S. prescribing information identifies conventional oral-tablet excipients, including lactose monohydrate, corn starch, pregelatinized corn starch, povidone, magnesium stearate, hypromellose, talc, titanium dioxide, and iron oxide colorants.[1]

The precise role of each excipient is commercially important:

Excipient class	Likely function in Natazia	Commercial opportunity
Lactose monohydrate	Diluent and tablet mass builder	Direct-compression and low-moisture grades
Corn starch	Filler and disintegration support	Controlled particle-size grades
Pregelatinized starch	Binder and disintegrant	Improved compactability and process robustness
Povidone	Binder and granulation aid	Molecular-weight and viscosity optimization
Magnesium stearate	Lubricant	Low-level lubrication with minimal dissolution impact
Hypromellose	Film-forming coating polymer	Ready-to-use colored coating systems
Talc	Anti-tacking and coating aid	Low-residue, controlled-particle-size grades
Titanium dioxide	Opacifier and whitening agent	Alternative pigments and regulatory-compliant coating systems
Iron oxides	Tablet color differentiation	Stable, reproducible color systems

The excipient list is conventional, but the combination must perform across several tablet strengths. A supplier that can offer a validated excipient platform for all five tablet types has greater commercial value than a commodity supplier selling a single filler.

How strong is Natazia’s formulation and excipient patent estate?

Natazia’s strongest formulation protection is likely to depend on the complete product combination rather than on individual excipients. Lactose, starch, povidone, magnesium stearate, hypromellose, talc, and iron oxide are established pharmaceutical excipients with extensive prior use.

A new patent strategy would therefore be more credible around:

• Specific ratios of estradiol valerate, dienogest, and excipients.
• Granulation or blending processes that improve hormone uniformity.
• Coating systems that distinguish tablet phases without affecting dissolution.
• Moisture-control systems that protect steroid stability.
• Manufacturing sequences that reduce cross-contamination.
• Packaging configurations linked to regimen compliance.
• Alternative excipient systems that preserve bioequivalence while improving manufacturability.

A patent directed only to the use of lactose, starch, povidone, or magnesium stearate would face substantial novelty and obviousness risk. A narrower claim covering a validated process window, specific particle-size distribution, or multi-strength manufacturing sequence could be more defensible.

What formulation patents could protect Natazia or a generic equivalent?

Potential formulation claims fall into five categories.

Low-dose hormone uniformity

Dienogest and estradiol valerate are present at low milligram quantities in some tablet phases. Claims could focus on ordered mixing, carrier particle size, geometric dilution, granulation endpoint, or blend uniformity.

The commercial value is high because content-uniformity failures can cause batch rejection and regulatory delay. The technical challenge is proving that the claimed excipient system, rather than routine process control, produces the result.

Multi-strength tablet manufacturing

A manufacturer may seek claims covering a common excipient platform used for all active strengths. This can reduce tooling changes, cleaning complexity, and raw-material inventories.

The most valuable claims would connect the formulation to measurable outcomes such as:

• Blend uniformity;
• Tablet weight variation;
• Dissolution similarity;
• Reduced segregation;
• Lower cross-contamination;
• Longer stability under accelerated conditions.

Film coating and visual differentiation

Natazia requires multiple tablet colors. Film coating can be optimized for opacity, color stability, low weight gain, and mechanical resistance during packaging.

Commercially relevant alternatives include:

• Hypromellose-based ready-mix coatings;
• Polyvinyl alcohol-based coating systems;
• Iron-oxide pigment systems;
• Titanium-dioxide-free coatings where regulatory or market preferences require them;
• Coatings with improved resistance to abrasion and blister-pack transfer.

A coating patent is more commercially defensible when it claims a defined coating composition and performance profile rather than color alone.

Moisture and stability control

Steroid tablets can be sensitive to formulation moisture, packaging conditions, and coating permeability. Excipient suppliers can compete through low-moisture lactose, controlled-moisture starch, high-purity povidone, and barrier coating systems.

Blister-pack selection is part of the formulation strategy. Cold-form aluminum and high-barrier polymer systems can reduce moisture and oxygen exposure, although packaging changes require stability and regulatory support.

Dissolution and bioequivalence

A generic manufacturer cannot assume that any inactive-ingredient substitution is commercially neutral. Changes in lubricant level, granulation method, disintegrant type, or coating weight can alter dissolution and complicate bioequivalence.

The strongest excipient opportunity is a platform that delivers:

• Comparable dissolution across all active phases;
• Consistent tablet hardness;
• Acceptable friability;
• Low variability in hormone release;
• A manageable SUPAC or ANDA change-control pathway.

What is the FDA regulatory status of Natazia?

Natazia was approved by the FDA in 2010 as a combined oral contraceptive containing estradiol valerate and dienogest.[1] It is regulated as a prescription drug, and generic competition would generally proceed through the abbreviated new drug application pathway.

An ANDA applicant would need to address:

• Pharmaceutical equivalence;
• Bioequivalence;
• Active-ingredient strength and dosage form;
• Tablet appearance and identification;
• Dissolution performance;
• Stability;
• Impurity control;
• Inactive-ingredient safety;
• Labeling and packaging configuration.

The FDA Inactive Ingredient Database can support regulatory assessment of excipient substitutions, but prior use in a different route, dosage form, or maximum daily amount does not automatically eliminate the need for product-specific justification.[2]

What is the Orange Book status of Natazia?

The Orange Book is the principal FDA source for approved drug products, therapeutic-equivalence evaluations, patent listings, and exclusivity information.[3] Natazia’s commercial exclusivity analysis requires separate review of:

• Listed patents;
• Patent expiration dates;
• Pediatric exclusivity;
• Any patent-use codes;
• Approved generic entries;
• Paragraph IV certifications;
• Current marketing status.

The relevant strategic point is that Natazia’s original regulatory exclusivity and any listed-patent protection are separate from excipient differentiation. An excipient supplier cannot rely on the brand’s regulatory history to prevent a generic from using a different inactive-ingredient system.

Where a listed patent claims a method of contraception or a specific dosage regimen, a generic applicant may face a Paragraph IV challenge or may use a section viii statement to omit a patented method, depending on the patent-use code and label scope.[4]

When does Natazia lose exclusivity and what does that mean for generic entry?

Natazia’s first-mover protection is no longer based solely on the original approval date. Commercial entry depends on the surviving patent estate, FDA-listed patents, litigation, settlements, and whether an ANDA applicant can launch at risk.

A generic launch could take several forms:

Launch scenario	Excipient implication	Commercial effect
Full formulation copy	Lowest development risk	Direct price competition
Same actives, different excipients	Greater formulation work	Potential differentiation in cost or tolerability
Same actives with alternative coating	Moderate technical risk	Lower coating cost or improved appearance
Authorized generic	Fastest commercial route if available	Limits third-party generic pricing advantage
At-risk launch after Paragraph IV	High litigation exposure	Potential rapid share capture with damages risk
Delayed entry after settlement	Lower legal risk	Staged competitive erosion

The absence of a novel delivery system reduces the likelihood that excipients alone will delay entry for a long period. The practical barrier is more likely to be the cost of developing and validating five tablet types in a single packaged regimen.

Which companies could challenge Natazia or supply competing excipients?

Potential generic entrants would include established manufacturers with women’s-health portfolios and experience in complex oral solid dosage products. Relevant capabilities include:

• Multi-product oral contraceptive manufacturing;
• Hormonal active pharmaceutical ingredient handling;
• Low-dose blend uniformity;
• Multi-color film coating;
• Blister packaging;
• ANDA development;
• Hormone-containment and cleaning validation.

Excipient suppliers with commercial opportunities include manufacturers of:

• Direct-compression lactose;
• Pregelatinized starch;
• Povidone;
• Magnesium stearate;
• Hypromellose coating systems;
• Iron oxide and titanium-dioxide pigment systems;
• High-barrier blister materials.

The most attractive supplier position is a qualified formulation package that reduces development time. Selling individual excipients creates price competition. Selling a validated combination with application data creates switching costs and supports premium pricing.

What manufacturing and intellectual-property barriers affect Natazia?

The principal manufacturing barriers are operational rather than fundamental chemistry barriers.

Cross-contamination control

Hormonal products require validated cleaning procedures and segregation controls. A facility producing multiple strengths must demonstrate that higher-dose batches do not contaminate lower-dose tablets.

Blend segregation

Differences in particle size, density, and electrostatic behavior can cause segregation during transfer and compression. Excipient particle engineering can materially affect batch consistency.

Coating reproducibility

Five tablet appearances must remain within color and surface-quality specifications. Pigment dispersion, spray rate, inlet temperature, and tablet-bed movement all affect appearance.

Packaging accuracy

A regimen-based product requires correct tablet order and clear phase identification. Packaging defects can create medication errors and regulatory recalls.

Stability

Excipient moisture, coating permeability, and blister-barrier performance can affect assay, impurities, dissolution, and appearance during shelf life.

These barriers support process patents, trade secrets, and supplier qualification advantages. They do not necessarily create a durable blocking position against a well-funded generic manufacturer.

What commercial opportunities exist in Natazia’s excipient supply chain?

The highest-value opportunities are concentrated in five areas.

Premium coating systems

A ready-to-use coating system that produces five stable shades with low weight gain can reduce development and scale-up work. Suppliers can differentiate through pigment dispersion, color consistency, and accelerated-stability data.

Low-dose content-uniformity platforms

Excipient combinations designed for ordered mixing and low-dose steroid distribution can support generic development. Application data should focus on blend uniformity, assay variability, and dissolution.

Lactose-free or reduced-lactose alternatives

Natazia uses lactose-containing excipients according to the FDA labeling. A lactose-free generic could target patients and markets where lactose avoidance is commercially relevant, provided the alternative system supports equivalence and tablet performance.

Contract development and manufacturing

Companies with hormone containment, multi-strength compression, film coating, and blister packaging can offer an integrated service. The complex regimen creates more value for a qualified contract manufacturer than a simple single-strength tablet.

Packaging and adherence systems

Calendarized blister packs, digital adherence tools, and clearer tablet-phase labeling can support lifecycle management. These opportunities are more likely to produce brand differentiation than a routine filler substitution.

How does Natazia compare with conventional combined oral contraceptives?

Natazia differs from many combined oral contraceptives because it uses estradiol valerate rather than ethinyl estradiol and combines it with dienogest in a four-phase regimen.[1]

Attribute	Natazia	Conventional monophasic product
Estrogen component	Estradiol valerate	Often ethinyl estradiol
Progestin	Dienogest	Product-dependent
Active phases	Four	Usually one
Excipient complexity	High	Lower
Color-control burden	High	Moderate
Generic manufacturing	More complex	Generally simpler
Packaging dependence	High	Moderate
Opportunity for process differentiation	Meaningful	Often narrower

Natazia’s differentiated hormonal regimen creates a more complex generic-development project. It does not, by itself, establish a strong barrier to excipient substitution.

What is the revenue exposure to generic competition?

Bayer generally reports women’s-health performance at a portfolio level rather than disclosing standalone Natazia revenue in its public financial reporting.[5] Product-level revenue exposure therefore cannot be reliably quantified from standard annual-report disclosures.

The commercial impact of generic entry would depend on:

• Current U.S. prescription volume;
• Net price after rebates;
• Brand loyalty;
• Number of approved ANDAs;
• Timing of first generic entry;
• Payer substitution rules;
• International pricing;
• Whether Bayer has an authorized generic or settlement arrangement.

For excipient and contract-manufacturing companies, the opportunity is less dependent on Natazia’s absolute brand revenue than on the number of potential generic development programs and the need to manufacture five distinct tablet presentations.

What patent litigation and settlement issues matter?

The principal litigation risks are:

• Paragraph IV challenges to listed patents;
• Patent-use-code disputes;
• Method-of-use claims covering contraception or bleeding-related indications;
• Inequitable-conduct allegations;
• Formulation patent validity challenges;
• Launch-at-risk damages;
• Settlement agreements that delay generic entry.

A settlement can preserve a period of branded sales while establishing a later generic entry date. It can also permit an authorized generic or limit the scope of a commercial launch. Excipient suppliers should treat settlement timing as a procurement and qualification variable because a delayed launch can defer commercial volumes for years.

Key Takeaways

• Natazia uses estradiol valerate and dienogest in a five-tablet-type, 28-day regimen.
• Its excipient system is conventional but operationally complex.
• The main opportunities are low-dose uniformity, film coating, color control, moisture protection, blister packaging, and manufacturing validation.
• Broad patents on common excipients are unlikely to provide strong protection.
• Narrow process, coating, stability, and multi-strength manufacturing claims have greater commercial potential.
• Generic competition would require control of multiple tablet strengths, hormonal cross-contamination, dissolution, packaging, and color specifications.
• The FDA regulatory pathway is generally an ANDA, subject to patent certifications and bioequivalence requirements.
• Product-level Natazia revenue is not separately disclosed by Bayer, limiting precise revenue-exposure modeling.
• Excipient suppliers should sell application-qualified systems rather than undifferentiated commodity materials.

FAQs

Can a generic Natazia use different excipients?

Yes. A generic may use different inactive ingredients if the product satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, safety, stability, dissolution, and labeling.

Is lactose the main commercial vulnerability in the Natazia formulation?

No. Lactose substitution is technically feasible, but the larger development challenge is maintaining content uniformity and dissolution across all active tablet phases.

Which excipient has the highest strategic value for Natazia generics?

A validated film-coating and low-dose blending platform has greater strategic value than a single commodity excipient because it addresses several product-specific manufacturing risks.

Can a coating patent block a Natazia generic?

Potentially, but only if the patent claims a legally enforceable coating composition or process that the generic would infringe. Color similarity alone is unlikely to provide broad protection.

Would a lactose-free Natazia generic have a commercial advantage?

It could create a niche positioning advantage, but the commercial benefit would depend on payer coverage, patient demand, tablet performance, and whether the alternative formulation remains bioequivalent and cost-competitive.

References

1. U.S. Food and Drug Administration. (2023). Natazia (estradiol valerate and estradiol valerate/dienogest) prescribing information. Bayer HealthCare Pharmaceuticals Inc.

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2018). Hatch-Waxman amendments: Questions and answers. FDA.

5. Bayer AG. (2023). Annual report 2023. Leverkusen, Germany: Bayer AG.